XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, was featured in an article titled “Is Mescaline a Key Component in the Future of Medicine? XPhyto Aims to Find Out.” The article notes that mescaline (3,4,5-trimethoxyphenethylamine), the magical alkaloid found in the peyote cactus and similar cacti, could be the next vital ingredient in psychedelic drug formulations. Citing recent data that supports the substance’s potential to treat disorders such as depression, anxiety, post-traumatic stress disorder (“PTSD”) and alcohol and drug-use issues, the article states that researchers believe mescaline could “unlock a novel arsenal to battle otherwise difficult-to-treat conditions.” The article points out that XPhyto Therapeutics is developing mescaline synthesis processes, which could provide controlled microdoses; the article also noted that XPhyto has expertise in transdermal patches, sublingual strips and similar delivery systems. “If you look at psychedelics like mescaline, if you want to scale it, medicalize it, and modernize it, you have to synthesize it, using a biotechnology process on an industrial scale,” said XPhyto CEO Hugh Rogers in the article. “We don’t think that we’ll ever get to a point where — at least in the mainstream — people will be consuming peyote cactus. From a regulatory perspective, it’s too complex as a multi-compound plant extract through the FDA or Health Canada. It also gets very complicated from a drug delivery perspective.”
To view the full article, visit https://ibn.fm/O4059
About XPhyto Therapeutics Corp.
XPhyto Therapeutics is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral-health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. XPhyto has research and development operations in North America and Europe, with an operational focus in Germany. The company is currently focused on regulatory approval and commercialization of medical products for European markets. For more information about this company, please visit www.XPhyto.com
NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
InvestorWire is part of the InvestorBrandNetwork.